ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms

British Journal of Haematology

Volumn 140, Issue 2, 2008, Pages 181-190

  Kuroda, Junya ^a   Kimura, Shinya ^b   Andreeff, Michael ^c   Ashihara, Eishi ^b   Kamitsuji, Yuri ^b   Yokota, Asumi ^b   Kawata, Eri ^b   Takeuchi, Miki ^b   Tanaka, Ruriko ^b   Murotani, Yoshihide ^b   Matsumoto, Yosuke ^a   Tanaka, Hideo ^d   Strasser, Andreas ^e   Taniwaki, Masafumi ^a   Maekawa, Taira ^b  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

^c UNIVERSITY OF TEXAS   (United States)

^d HIROSHIMA UNIVERSITY   (Japan)

^e WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

ABT 737; Bcr Abl; Chronic myeloid leukaemia; Homoharringtonine; Imatinib

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ABELSON KINASE; HOMOHARRINGTONINE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL KILLING; CHRONIC MYELOID LEUKEMIA; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MALE; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BIPHENYL COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; HARRINGTONINES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES; SURVIVAL ANALYSIS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 37249013938     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06899.x     Document Type: Article

References (39)

1. Aichberger, K.J., Mayerhofer, M., Krauth, M.T., Skvara, H., Florian, S., Sonneck, K., Akgul, C., Derdak, S., Pickl, W.F., Wacheck, V., Selzer, E., Monia, B.P., Moriggl, R., Valent, P. Sillaber, C. (2005) Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood, 105, 3303 3311.
2. Amarante-Mendes, G.P., Naekyung Kim, C., Liu, L., Huang, Y., Perkins, C.L., Green, D.R. Bhalla, K. (1998) Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood, 91, 1700 1705.
3. Barnes, D.J., Palaiologou, D., Panousopoulou, E., Schultheis, B., Yong, A.S., Wong, A., Pattacini, L., Goldman, J.M. Melo, J.V. (2005) Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Research, 5, 8912 8919.
4. Chauhan, D., Velankar, M., Brahmandam, M., Hideshima, T., Podar, K., Richardson, P., Schlossman, R., Ghobrial, I., Raje, N., Munshi, N. Anderson, K.C. (2007) A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene, 26, 2374 2380.
5. Chow, K.U., Ries, J., Weidmann, E., Pourebrahim, F., Napieralski, S., Stieler, M., Boehrer, S., Rummel, M.J., Stein, J., Hoelzer, D. Mitrou, P.S. (2000) Induction of apoptosis using 2′,2′ difluorodeoxycytidine (gemcitabine) in combination with antimetabolites or anthracyclines on malignant lymphatic and myeloid cells. Antagonism or synergism depends on incubation schedule and origin of neoplastic cells. Annals of Hematology, 79, 485 492.
6. Copland, M., Hamilton, A., Elrick, L.J., Baird, J.W., Allan, E.K., Jordanides, N., Barow, M., Mountford, J.C. Holyoake, T.L. (2006) Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood, 107, 4532 4539.
7. Cory, S. Adams, J.M. (2002) The Bcl2 family: regulators of the cellular life-or-death switch. Nature Reviews Cancer, 2, 647 656.
8. Dai, Y., Rahmani, M., Corey, S.J., Dent, P. Grant, S. (2004) A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. The Journal of Biological Chemistry, 279, 34227 34239.
9. van Delft, M.F., Wei, A.H., Mason, K.D., Vandenberg, C.J., Chen, L., Czabotar, P.E., Willis, S.N., Scott, C.L., Day, C.L., Cory, S., Adams, J.M., Roberts, A.W. Huang, D.C. (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell, 10, 389 399.
10. Deng, J., Carlson, N., Takeyama, K., Dal Cin, P., Shipp, M. Letai, A. (2007) BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell, 12, 171 185.
11. Donato, N.J., Wu, J.Y., Stapley, J., Lin, H., Arlinghaus, R., Aggarwal, B.B., Shishodia, S., Albitar, M., Hayes, K., Kantarjian, H. Talpaz, M. (2004) Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Research, 64, 672 677.
12. Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N. Sawyers, C.L. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 293, 876 880.
13. van den Heuvel-Eibrink, M.M., Wiemer, E.A., de Boevere, M.J., van der Holt, B., Vossebeld, P.J., Pieters, R. Sonneveld, P. (2001) MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. Blood, 97, 3605 3611.
14. Holtz, M.S., Forman, S.J. Bhatia, R. (2005) Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia, 19, 1034 1041.
15. Ito, T., Tanaka, H. Kimura, A. (2007) Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn. European Journal of Haematology, 78, 417 431.
16. Kimura, S., Naito, H., Segawa, H., Kuroda, J., Yuasa, T., Sato, K., Yokota, A., Kamitsuji, Y., Kawata, E., Ashihara, E., Nakaya, Y., Naruoka, H., Wakayama, T., Nasu, K., Asaki, T., Niwa, T., Hirabayashi, K. Maekawa, T. (2005) NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood, 106, 3948 3954.
17. Kohl, T.M., Hellinger, C., Ahmed, F., Buske, C., Hiddemann, W., Bohlander, S.K. Spiekermann, K. (2007) BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. Leukemia, 21, 1763 1772.
18. Konopleva, M., Contractor, R., Tsao, T., Samudio, I., Ruvolo, P.P., Kitada, S., Deng, X., Zhai, D., Shi, Y.X., Sneed, T., Verhaegen, M., Soengas, M., Ruvolo, V.R., McQueen, T., Schober, W.D., Watt, J.C., Jiffar, T., Ling, X., Marini, F.C., Harris, D., Dietrich, M., Estrov, Z., McCubrey, J., May, W.S., Reed, J.C. Andreeff, M. (2006) Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell, 10, 375 388.
19. Kuroda, J., Kimura, S., Segawa, H., Kobayashi, Y., Yoshikawa, T., Urasaki, Y., Ueda, T., Enjo, F., Tokuda, H., Ottmann, O.G. Maekawa, T. (2003) The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. Blood, 102, 2229 2235.
20. Kuroda, J., Puthalakath, H., Cragg, M.S., Kelly, P.N., Bouillet, P., Huang, D.C., Kimura, S., Ottmann, O.G., Druker, B.J., Villunger, A., Roberts, A.W. Strasser, A. (2006) Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proceedings of the National Academy of Sciences of the United States of America, 103, 14907 14912.
21. Kuroda, J., Kimura, S., Strasser, A., Andreeff, M., O'reilly, L.A., Ashihara, E., Kamitsuji, Y., Yokota, A., Kawata, E., Takeuchi, M., Tanaka, R., Tabe, Y., Taniwaki, M. Maekawa, T. (2007) Apoptosis-based dual molecular targeting by INNO-406, a second generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of anti-apoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Cell Death and Differentiation, 14, 1667 1677.
22. Letai, A., Bassik, M.C., Walensky, L.D., Sorcinelli, M.D., Weiler, S. Korsmeyer, S.J. (2002) Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell, 2, 183 192.
23. Mahon, F.X., Deininger, M.W., Schultheis, B., Chabrol, J., Reiffers, J., Goldman, J.M. Melo, J.V. (2000) Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood, 96, 1070 1079.
24. Mason, K.D., Carpinelli, M.R., Fletcher, J.I., Collinge, J.E., Hilton, A.A., Ellis, S., Kelly, P.N., Ekert, P.G., Metcalf, D., Roberts, A.W., Huang, D.C. Kile, B.T. (2007) Programmed anuclear cell death delimits platelet life span. Cell, 128, 1173 1186.
25. Melo, J.V. Deininger, M.W. (2004) Biology of chronic myelogenous leukemia - signaling pathways of initiation and transformation. Hematology/Oncology Clinics of North America, 18, 545 568.
26. Naito, H., Kimura, S., Nakaya, Y., Naruoka, H., Kimura, S., Ito, S., Wakayama, T., Maekawa, T. Hirabayashi, K. (2006) In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations. Leukemia Research, 30, 1443 1446.
27. O'Hare, T., Walters, D.K., Stoffregen, E.P., Jia, T., Manley, P.W., Mestan, J., Cowan-Jacob, S.W., Lee, F.Y., Heinrich, M.C., Deininger, M.W. Druker, B.J. (2005) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Research, 65, 4500 4505.
28. Oltersdorf, T., Elmore, S.W., Shoemaker, A.R., Armstrong, R.C., Augeri, D.J., Belli, B.A., Bruncko, M., Deckwerth, T.L., Dinges, J., Hajduk, P.J., Joseph, M.K., Kitada, S., Korsmeyer, S.J., Kunzer, A.R., Letai, A., Li, C., Mitten, M.J., Nettesheim, D.G., Ng, S., Nimmer, P.M., O'Connor, J.M., Oleksijew, A., Petros, A.M., Reed, J.C., Shen, W., Tahir, S.K., Thompson, C.B., Tomaselli, K.J., Wang, B., Wendt, M.D., Zhang, H., Fesik, S.W. Rosenberg, S.H. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature, 435, 677 681.
29. Quintás-Cardama, A., Kantarjian, H., Garcia-Manero, G., O'Brien, S., Faderl, S., Estrov, Z., Giles, F., Murgo, A., Ladie, N., Verstovsek, S. Cortes, J. (2007) Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer, 109, 248 255.
30. Reed, J.C. Pellecchia, M. (2005) Apoptosis-based therapies for hematologic malignancies. Blood, 106, 408 418.
31. Segawa, H., Kimura, S., Kuroda, J., Sato, K., Yokota, A., Kawata, E., Kamitsuji, Y., Ashihara, E., Yuasa, T., Fujiyama, Y., Ottmann, O.G. Maekawa, T. (2005) Zoledronate synergises with imatinib mesylate to inhibit Ph primary leukaemic cell growth. British Journal of Haematology, 130, 558 560.
32. Shah, N.P., Nicoll, J.M., Nagar, B., Gorre, M.E., Paquette, R.L., Kuriyan, J. Sawyers, C.L. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell, 2, 117 125.
33. Skorski, T. (2002) BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability. Oncogene, 21, 8591 8604.
34. Strasser, A., O'Connor, L. Dixit, V.M. (2000) Apoptosis signaling. Annual review of Biochemistry, 69, 217 245.
35. Tang, R., Faussat, A.M., Majdak, P., Marzac, C., Dubrulle, S., Marjanovic, Z., Legrand, O. Marie, J.P. (2006) Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Molecular Cancer Therapeutics, 5, 723 731.
36. Urasaki, Y., Ueda, T., Yoshida, A., Fukushima, T., Takeuchi, N., Tsuruo, T. et al (1996) Establishment of a daunorubicin-resistant cell line which shows multi-drug resistance by multifactorial mechanisms. Anticancer Research, 16, 709 714.
37. Willis, S.N., Fletcher, J.I., Kaufmann, T., van Delft, M.F., Chen, L., Czabotar, P.E., Ierino, H., Lee, E.F., Fairlie, W.D., Bouillet, P., Strasser, A., Kluck, R.M., Adams, J.M. Huang, D.C. (2007) Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science, 315, 856 859.
38. Yokota, A., Kimura, S., Masuda, S., Ashihara, E., Kuroda, J., Sato, K., Kamitsuji, Y., Kawata, E., Deguchi, Y., Urasaki, Y., Terui, Y., Ruthardt, M., Ueda, T., Hatake, K., Inui, K. Maekawa, T. (2007) INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system and cyclosporine A augments its in vivo activity. Blood, 109, 306 314.
39. Zhang, H., Nimmer, P.M., Tahir, S.K., Chen, J., Fryer, R.M., Hahn, K.R., Iciek, L.A., Morgan, S.J., Nasarre, M.C., Nelson, R., Preusser, L.C., Reinhart, G.A., Smith, M.L., Rosenberg, S.H., Elmore, S.W. Tse, C. (2007) Bcl-2 family proteins are essential for platelet survival. Cell Death and Differentiation, 14, 943 951.